StreetInsider.com News Articles

Edwards Lifesciences faces stock risk ahead of trial results says Stifel

Thu, 22 Oct 2026 11:01:10 -0400

Investing.com -- Edwards Lifesciences may face more downside than upside risk heading into the TCT 2026 medical meeting, according to physician feedback gathered by Stifel ahead of the November 2 PROGRESS trial data release.

The PROGRESS trial examines whether transcatheter aortic valve replacement proves beneficial for patients with moderate aortic stenosis. Stifel spoke with four senior interventional cardiologists who expect the trial to meet its composite primary endpoint, which measures death or heart-failure events at two years.

The physicians indicated the trial will likely achieve its endpoint through the heart-failure component rather than mortality benefits. The doctors noted that two years of

Edwards Lifesciences faces stock risk ahead of trial results says Stifel

Thu, 22 Oct 2026 11:01:10 -0400

The physicians indicated the trial will likely achieve its endpoint through the heart-failure component rather than mortality benefits. The doctors noted that two years of

FDA clears Edwards Lifesciences PASCAL system for tricuspid repair

Wed, 21 Oct 2026 09:00:55 -0400

Edwards Lifesciences Corporation (NYSE: EW) announced that the U.S. Food and Drug Administration has approved its PASCAL Precision system for tricuspid valve repair, expanding the Irvine, California-based company's transcatheter valve therapy portfolio.

The system is indicated for patients with symptomatic severe tricuspid regurgitation who remain symptomatic despite optimal medical therapy and are deemed at intermediate or greater risk for surgery. Eligibility requires approval by a multidisciplinary heart team for transcatheter edge-to-edge tricuspid valve repair.

According to the company's press release, Edwards now claims to be the only company offering a portfolio of both repair and replacement transcatheter therapies for the mitral and

FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease

Wed, 21 Oct 2026 09:00:00 -0400

Recent FDA Approval of PASCAL Ace with Capture Clarity Simplifies Mitral TEER Procedures for Clinicians

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tricuspid valve repair (T-TEER) by a multidisciplinary heart team. With this approval, Edwards is

FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease

Wed, 21 Oct 2026 09:00:00 -0400

Recent FDA Approval of PASCAL Ace with Capture Clarity Simplifies Mitral TEER Procedures for Clinicians

Edwards Lifesciences (EW) PT Lowered to $90 at Baird

Thu, 15 Oct 2026 07:22:04 -0400

Baird analyst David Rescott lowered the price target on Edwards Lifesciences (NYSE: EW) to $90.00 (from $94.00) while maintaining a Neutral rating.

U.S. MedTech stocks: Q3 earnings preview